Teva’s Layoffs Signal Deeper Fault Lines In The Pharma Business Model

The recent announcement that Teva Pharmaceuticals will lay off roughly 2,400 employees–approximately 8% of its global workforce–is a significant development in a sector already under strain. This move aims to save $700 million by 2027 as Teva attempts to rebalance its role as both a generics manufacturer…

Continue Reading


News Source: www.forbes.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *